NAMPT and laryngotracheoesophageal cleft: The main limitation of the present study is the limited number of samples; therefore an expansion of these studies to a larger cohort could confirm our findings and further demonstrate the utility of TTHY, RET4, PROF1, S10A9 and GDIR1, and NAMPT as biomarkers of LC onset in IPF patients.